Regular ArticleA Phase III Trial of Ifosfamide with or without Cisplatin in Carcinosarcoma of the Uterus: A Gynecologic Oncology Group Study☆
References (30)
- et al.
Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group Study
Am J Obstet Gynecol
(1989) - et al.
Cyclophosphamide, vincristine, Adriamycin and dimethyltriazeno-imidazolecarboxamide (CYVADIC) for sarcomas of the female genital tract
Gynecol Oncol
(1982) - et al.
Treatment of advanced uterine sarcomas with vincristine, actinomycin D, and cyclophosphamide
Gynecol Oncol
(1983) - et al.
Phase II trial of hydroxyurea, dacarbazine (DTIC), and etoposide (VP-16) in mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group Study
Gynecol Oncol
(1996) - et al.
A phase II study of paclitaxel in leiomyosarcomas of the uterus: a Gynecologic Oncology Group Study
Gynecol Oncol
(1999) - et al.
Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcoma of the adult. EORTC Soft Tissue and Bone Sarcoma Group
Ann Oncol
(1994) - et al.
Estrogen and progesterone receptors in uterine sarcomas
Obstet Gynecol
(1986) - et al.
A randomized study of adriamycin with and without DTIC in advanced uterine sarcomas
Cancer
(1983) - et al.
Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study
Cancer Treat Rep
(1986) - et al.
Phase II trial of etoposide in the management of advanced or recurrent mixed mesodermal sarcomas of the uterus
Cancer Treat Rep
(1987)
VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory testicular cancer
Cancer Chemother Pharmacol
Nonparametric estimation from incomplete observations
J Am Stat Assoc
Evaluation of survival data and two new rank order statistics arising in its consideration
Cancer Chemother Rep
Regression models and life-tables
J R Stat Soc B
Cited by (224)
Adenocarcinoma of the uterine corpus and sarcomas of the uterus
2023, DiSaia and Creasman Clinical Gynecologic OncologyUterine carcinosarcoma
2023, Diagnosis and Treatment of Rare Gynecologic CancersEfficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26)
2022, Gynecologic OncologyCitation Excerpt :The disease stage (stage I-II vs III-IV), age (≥70 years) and the presence of macroscopic residual disease are considered as poor prognostic factors, whereas the primary location, with a somewhat worse prognosis for women with OC, and the histological type may be predictive factors for the efficacy of chemotherapy or radiotherapy [5–9]. For both OC and US, the backbone treatment remains complete surgical cytoreduction followed, even in early stage, by platinum-based chemotherapy, usually with the combination of carboplatin-paclitaxel or with cisplatin and ifosfamide [8,10–15]. Recently, a phase III randomized trial in patients with carcinosarcoma of the uterus or ovary has reported that the combination of paclitaxel and carboplatin is not inferior to the active regimen of paclitaxel and ifosfamide and thus should be standard treatment for those patients [16].
Adjuvant therapy and prognosis in uterine carcinosarcoma
2021, Journal of the Formosan Medical AssociationUterine carcinosarcoma: An overview
2021, Critical Reviews in Oncology/Hematology
- ☆
Please address reprint requests to GOG Administrative Office, Suite 1945, 1234 Market Street, Philadelphia, PA 19107.
- 2
Present address: Department of Gynecologic Oncology, St. Vincent Hospitals and Health Services, 2001 East 86th Street, Indianapolis, IN 46260.